FDA Awards National Priority Vouchers to Three Psychedelic Programs, Compressing Review Times to One to Two Months
Compass Pathways, Usona Institute, and Otsuka-acquired Transcend Therapeutics have been selected for FDA's Commissioner's National Priority Voucher program for psilocybin and methylone, six days after President Trump's executive order on serious mental illness.
6 min read8 sources